Clinical Trials Blog

November 2025 clinical trial highlights

by Pulmonary Fibrosis Foundation
November 24, 2025
Doctor with lung scan

Clinical trial participants are essential in the quest for new treatments and a cure for pulmonary fibrosis (PF).

Each month, we'll highlight a few of the many trials enrolling volunteers. To view more available trials for various forms of interstitial lung disease (ILD), please visit the 🔍 PFF Clinical Trial Finder.


Seeking participants with IPF

ASPIRE

  • Study ID: NCT06588686
  • Trial Phase: Phase 2b
  • Intervention: Oral drug
  • Sponsor: Vicore Pharma AB
  • Study Contact: Thomas Eskildsen, MSc., Pharm. and Bernt Van Den Blink, MD, PhD (857.491.8478; info@aspire-ipf.com)

Learn more about this study

Learn more about this drug

Seeking participants with IPF

AURORA

  • Study ID: NCT06736990
  • Trial Phase: Phase 2
  • Intervention: Intravenous infusion
  • Sponsor: Calluna Pharma AS
  • Study Contact: Charlotte Kleiveland (+47.401.680.27; info@callunapharma.com)

Learn more about this study

Learn more about this drug

 

Sybil was an energetic college educator, eagerly anticipating retirement and travel with her husband. When she developed a persistent cough, she initially attributed it to seasonal allergies. After her husband encouraged her to see a doctor, Sybil was diagnosed with idiopathic pulmonary fibrosis (IPF).

Initially, Sybil felt hopeless but chose to focus on living. She established coping strategies, relied on her faith and family, and actively sought quality medical care. Following a successful lung transplant, Sybil now embraces each day with gratitude. 

As a PFF Ambassador, she encourages others on a similar path living with IPF. The Preparing for a Lung Transplant booklet* is one of many educational resources available to PF community members that are interested in learning about the lung transplant process.

*This booklet is for educational purposes only. It is vital to consult a medical professional when making any health decisions.

 

 Phase 2b IPF study presents new data

In September 2025, PureTech announced new data from the phase 2b open-label extension of its ELEVATE IPF study. These new results show that participants who completed 26 weeks of placebo or pirfenidone treatment in the randomized portion of the trial and then switched to deupirfenidone for an additional 26 weeks in the open label extension achieved stabilization of lung function. These findings were presented at the 2025 European Respiratory Society (ERS) Congress.

These findings reinforce the reproducibility of the blinded results with deupirfenidone and support its potential benefit for patients transitioning from standard of care.

Phase 2a IPF study meets its primary endpoint 

In May 2025, Endeavor BioMedicines announced positive results for its phase 2a WHISTLE-PF study, which evaluated the use of the oral drug taladegib. The study demonstrated that individuals with IPF who took taladegib experienced a reduction in pulmonary vessel volume, increased in lung volume, and reduced fibrosis. Additional findings indicated that those taking the drug exhibited improved lung function compared to the placebo group, successfully meeting the study's primary endpoint.


A primary endpoint is a key measurement researchers use to determine the efficacy of a medication or intervention. These findings are particularly noteworthy as taladegib was the only therapeutic that resulted in a reduction in pulmonary vessel volume. This further highlights taladegib's potential to reverse disease across multiple measures, representing a significant advancement for the IPF community.

 

 

If you have any questions or comments about this newsletter, please email partnerships@pulmonaryfibrosis.org.